Skip to content

US · ARTV · BIOTECHNOLOGY

Artiva Biotherapeutics, Inc. (ARTV) intrinsic value and stock valuation

$3.78as of 2026-11-21 · Mkt cap 286.47M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Artiva Biotherapeutics, Inc. DCF and intrinsic value

InvestorsCraft values ARTV with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ARTV’s statements →

Artiva Biotherapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92121 artivabio.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$0.00
20202025
Net income
-$-83.86M
20202025
Free cash flow
-$-79.34M
20202025
Total equity
$110M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$0.00$250K$33.5M$4.93M$2M
Operating income-$-90.61M-$-67.28M-$-30.67M-$-59.83M-$-53.27M
Net income-$-83.86M-$-58.49M-$-27.7M-$-58.39M-$-71.83M
EPSd-$-3.43M-$-2.4M-$-1.19M-$-3.32M-$-4.09M
Operating cash flow-$-76.75M-$-55.03M-$-47.43M-$-50.83M-$-15.3M
Capital expenditure-$-2.59M-$-640K-$-3.26M-$-6.3M-$-1.72M
Free cash flow-$-79.34M-$-55.67M-$-50.69M-$-57.13M-$-17.03M
Total assets$130.9M$209.6M$105.1M$133.1M$169.9M
Total debt$10.9M$14.4M$16.9M$19.5M$1.74M
Net debt-$-15.76M-$-25.88M-$-36.59M-$-83.08M-$-159.18M
Total equity$110M$186.6M-$-162.01M-$-140.7M-$-88.86M
Cash and short-term investments$108M$185.4M$77M$102.5M$160.9M
Income statement
20252024202320222021
Revenue$0.00$250K$33.5M$4.93M$2M
Cost of revenue$2.6M$0.00$0.00$0.00$0.00
Gross profit-$-2.6M$250K$33.5M$4.93M$2M
Research and development expenses$69.5M$50.3M$50.3M$44M$42.4M
Selling, general and administrative expenses$20.3M$17.2M$13.9M$20.8M$12.9M
Other expenses-$-1.8M$0.00$0.00$0.00$0.00
Operating expenses$88M$67.5M$64.2M$64.8M$55.3M
Cost and expenses$90.6M$67.5M$64.2M$64.8M$55.3M
Interest income$5.96M$5.35M$2.54M$1.29M$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$2.6M$2.43M$2.27M$1.16M$250K
Ebitda-$-81.27M-$-56.06M-$-25.36M-$-57.18M-$-71.58M
Operating income-$-90.61M-$-67.28M-$-30.67M-$-59.83M-$-53.27M
Total other income/expenses, net$6.75M$8.79M$3.05M$1.49M-$-18.55M
Income before tax-$-83.86M-$-58.49M-$-27.62M-$-58.34M-$-71.83M
Income tax expense$0.00$0.00$70K$50K$0.00
Net income-$-83.86M-$-58.49M-$-27.7M-$-58.39M-$-71.83M
Weighted average shares outstanding$24.4M$24.4M$23.3M$17.6M$17.6M
Weighted average diluted shares outstanding$24.4M$24.4M$23.3M$17.6M$17.6M
Balance sheet
20252024202320222021
Cash and short-term investments$108M$185.4M$77M$102.5M$160.9M
Net receivables$770K$150K$1.76M$530K$470K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$112.7M$188.6M$79.8M$104.7M$162.3M
Property, plant and equipment, net$17.4M$20.4M$24.6M$27.6M$4.08M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$240K$0.00
Total non-current assets$18.3M$21M$25.3M$28.4M$7.64M
Total assets$130.9M$209.6M$105.1M$133.1M$169.9M
Accounts payable$350K$1.12M$610K$1.1M$1.44M
Short-term debt$3.06M$3.74M$3.6M$3.49M$430K
Deferred revenue$0.00$0.00$0.00$10.9M$7.29M
Total current liabilities$13.1M$12.3M$12.2M$25.6M$19.3M
Long-term debt$7.88M$10.6M$13.3M$16M$1.31M
Deferred revenue, non-current$0.00$0.00$0.00$15.6M$21.7M
Total non-current liabilities$7.88M$10.7M$254.9M$248.1M$239.5M
Capital lease obligations$0.00$14.4M$16.9M$19.5M$1.74M
Total liabilities$21M$22.9M$267.1M$273.8M$258.8M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-330.55M-$-246.68M-$-181.31M-$-152.59M-$-93.8M
Accumulated other comprehensive income (loss)$100K-$-130K$310K$0.00$0.00
Total equity$110M$186.6M-$-162.01M-$-140.7M-$-88.86M
Total investments$81.3M$145.2M$23.5M$240K$0.00
Total debt$10.9M$14.4M$16.9M$19.5M$1.74M
Net debt-$-15.76M-$-25.88M-$-36.59M-$-83.08M-$-159.18M
Cash flow statement
20252024202320222021
Net income-$-83.86M-$-65.37M-$-28.72M-$-58.79M-$-71.83M
Depreciation and amortization$2.6M$2.43M$2.27M$1.16M$250K
Stock-based compensation$6.82M$6.98M$7.05M$6.58M$4.31M
Change in working capital-$-420K-$-330K-$-28.28M-$-3.87M$33.4M
Accounts receivable$80K$1.61M-$-1.23M-$-60K-$-470K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-760K$520K-$-410K$190K-$-1.24M
Net cash provided by operating activities-$-76.75M-$-55.03M-$-47.43M-$-50.83M-$-15.3M
Investments in property, plant and equipment-$-2.59M-$-640K-$-3.26M-$-6.3M-$-1.72M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$63.4M-$-120.46M-$-25.98M-$-6.3M-$-1.72M
Common stock issued$370K$166.5M$0.00$0.00$0.00
Common stock repurchased$0.00-$-4.18M-$-10K-$-10K$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$10K$162.2M$24.4M-$-1.26M$152.8M
Net change in cash-$-13.33M-$-13.27M-$-49.01M-$-58.39M$135.7M
Cash at end of period$27.2M$40.5M$53.8M$102.8M$161.2M
Operating cash flow-$-76.75M-$-55.03M-$-47.43M-$-50.83M-$-15.3M
Capital expenditure-$-2.59M-$-640K-$-3.26M-$-6.3M-$-1.72M
Free cash flow-$-79.34M-$-55.67M-$-50.69M-$-57.13M-$-17.03M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Artiva Biotherapeutics, Inc.

        Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.

        CEO
        Fred Aslan
        Employees
        104
        Beta
        2.19

        Explore

        Frequently asked questions

        What is the intrinsic value of Artiva Biotherapeutics, Inc. (ARTV)?

        InvestorsCraft does not currently publish an intrinsic value for ARTV. How the IC value is calculated.

        Is ARTV undervalued?

        InvestorsCraft does not publish an undervaluation signal for ARTV at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.